Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 1.00 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 1.00 |
| ▸ | CTSK | P43235 | 5/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226447 | 1.00 | TAS1R3 (1.00) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL4192862 | 1.00 | TAS1R3 (1.00) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL14362858 | 0.88 | TAS1R3 (0.78) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL3078403 | 0.88 | TAS1R3 (0.78) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL704949 | 0.88 | TAS1R3 (0.78) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL14605678 | 0.82 | TAS1R3 (0.70) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL13753385 | 0.81 | HDAC3 (0.68) | TAS1R3TAS1R1CTSBCTSSPIN1 | |
| SCHEMBL5429395 | 0.80 | TAS1R3 (0.66) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL7460576 | 0.79 | TAS1R3 (0.65) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL5438961 | 0.79 | TAS1R3 (0.65) | TAS1R3TAS1R1CTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003846-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | claimed |
| US-20020013360-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-01-31 | — | — | US | claimed |
| EP-1003846-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1998050533-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-6566373-B2 | For therapy of osteoporosis, periodontitis, and arthritis | SMITHKLINE BEECHAM CORPORATION | 2003-05-20 | — | — | US | disclosed |
| EP-1003846-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020013360-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-01-31 | — | — | US | disclosed |
| EP-1003846-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998050533-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013360-A1 | Protease inhibitors | CTSK, CTSV, CTSS | TAS1R3 3510/4885TAS1R1 4032/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.